Drug Trial Radar · NCT04567550
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
139
Actual
Start
Nov 20, 2020
Primary completion
Jun 18, 2026
Study completion Jun 18, 2026
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- Collaborators
- REGENXBIO Inc.
- First posted
- Sep 28, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 25 years, up to 89 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ABBV-RGX-314 is being developed as a novel, potential one-time gene therapy treatment for the treatment of Diabetic Retinopathy (DR) with and without Center-Involved Diabetic Macular Edema (CI-DME). DR is a chronic and progressive complication of diabetes mellitus. It is a sight-threatening disease characterized in the early stages by neuronal and vascular dysfunction in the retina, and later by neovascularization that leads to further deterioration of functional vision. Despite the availability of current treatments, diabetic retinopathy remains the leading cause of vision loss in working-age adults, those between the ages of 20 and 74. Existing treatment with anti-VEGF agents, although shown to be effective, are limited by short therapeutic half-lives, which then require frequent intravitreal injections over the patient's lifetime, resulting in increased risk of associated adverse events and significant treatment burden. Due to the burden of treatment, patients often do not closely adhere to treatment regimens and experience sub-optimal outcomes and a decline in vision.
Conditions
- Diabetic Retinopathy (DR)
- Center-Involved Diabetic Macular Edema (CI-DME)
Interventions
ABBV-RGX-314 Dose 1Genetic
AAV8 vector containing a transgene for anti-VEGF fab (Dose 1)
ABBV-RGX-314 Dose 2Genetic
AAV8 vector containing a transgene for anti-VEGF fab (Dose 2)
ABBV-RGX-314 Dose 3Genetic
AAV8 vector containing a transgene for anti-VEGF fab (Dose 3)
Topical SteroidDrug
Topical Steroid
ABBV-RGX-314 Dose 4Genetic
AAV8 vector containing a transgene for anti-VEGF fab (Dose 4)
AfliberceptBiological
Aflibercept
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Proportion of participants achieving a 2-step or greater improvement in DR in the study eye per the ETDRS-DRSS on 4 widefield digital stereoscopic fundus photography at Week 48Time frame: At Week 48
- Part 2: Mean change from baseline in Best Corrected Visual Acuity (BCVA) in the study eye at Week 54.Time frame: At Week 54
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
Retinal Research Institute, LLC
Phoenix, Arizona
Barnet Dulaney Perkins Eye Center
Phoenix, Arizona
California Retina Consultants
Bakersfield, California
Retina-Vitreous Associates Medical Group
Beverly Hills, California
Retinal Diagnostic Center
Campbell, California
Northern California Retina Vitreous Associates Medical Group, Inc.
Mountain View, California
California Eye Specialists Medical Group, Inc
Pasadena, California
Retinal Consultants San Diego
Poway, California
California Retina Consultants
Santa Barbara, California
Southeast Retina Center, PC
Augusta, Georgia
University Retina and Macula Associates, PC
Oak Forest, Illinois
Springfield Clinic
Springfield, Illinois
Wilmer Eye Institute/Johns Hopkins University School of Medicine
Baltimore, Maryland
Cumberland Valley Retina Consultants
Hagerstown, Maryland
Ophthalmic Consultants of Boston
Boston, Massachusetts
Sierra Eye Associates
Reno, Nevada
NJ Retina
Teaneck, New Jersey
Vision Research Center Eye Associates of New Mexico
Albuquerque, New Mexico
Duke University Eye Center
Durham, North Carolina
Mid Atlantic Retina
Philadelphia, Pennsylvania
Charles Retina Institute, P.C.
Germantown, Tennessee
Retina Research Institute of Texas, LLC
Abilene, Texas
Austin Clinical Research, LLC
Austin, Texas
Star Retina
Burleson, Texas
Retinal Consultants of Texas
The Woodlands, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.